| 5-R21-EB033687-02 |
Engineered immunotherapies neutralizing interleukin-22 binding protein |
Joel Collier |
Duke University |
| 5-R01-EB032791-02 |
Engineering of Polymeric Particles for Fetal Therapy |
W. Saltzman |
Yale University |
| 5-R21-EB029572-02 |
Enzyme-Powered Self-Propelled DNA Nanoparticles for Disruption and Antibiotic Delivery in Topical Biofilms |
Jeffrey Moran |
George Mason University |
| 5-R01-EB029455-04 |
Immunoengineered nanotechnology for targeted expansion of regulatory T cells |
Jamie Spangler |
Johns Hopkins University |
| 1-R01-EB035485-01 |
Nanostructured degradable bone cement for delivering novel antibiotics |
Shiladitya Sengupta |
Brigham And Women'S Hospital |
| 1-R15-EB031388-01 |
Nucleic Acid Nanoparticle-based Monoclonal Antibody Mimics |
Emil Khisamutdinov |
Ball State University |
| 1-R21-EB034942-01 |
Optimization of Tannic Acid Lipid Nanoparticles for a Therapeutic mRNA Vaccine Against Melanoma |
Owen Fenton |
Univ of North Carolina Chapel Hill |
| 5-R21-EB033183-02 |
Photoelectroporation: Biomacromolecule delivery via nanoscale light-amplified voltage generators |
Julie Champion |
Georgia Institute of Technology |
| 5-R01-EB028078-04 |
Plasmonic nanoparticle-mediated immunotherapy to treat metastatic cancer |
Tuan Vo-Dinh |
Duke University |
| 5-R21-EB032991-03 |
Rational Design of Oral Drugs Targeting Mucosa Delivery |
Qun Wang |
Iowa State University |
